All In Biotech

NDA 011757 · Pfizer

Depo-Medrol

Methylprednisolone Acetate · Injection

Last checked: Nov 20, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1959

May 27, 1959

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,078

579 Phase 3, 236 recruiting

FAERS reports

8,121

6,901 serious, 1,047 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of leukemias and lymphomas. Nervous System : Cerebral edema associated...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 27, 1959 Original approval · Type 2 - New Active Ingredient
3 products under this application
  • DEPO-MEDROL · METHYLPREDNISOLONE ACETATE 40MG/ML · INJECTABLE, INJECTION · Prescription · TE AB
  • DEPO-MEDROL · METHYLPREDNISOLONE ACETATE 80MG/ML · INJECTABLE, INJECTION · Prescription · TE AB
  • DEPO-MEDROL · METHYLPREDNISOLONE ACETATE 20MG/ML · INJECTABLE, INJECTION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylprednisolone" as an intervention, any sponsor and status, largest first.

All 2,078 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain1,628
  • off label use1,337
  • drug ineffective1,334
  • rheumatoid arthritis1,294
  • fatigue1,220
  • headache1,137
  • joint swelling967
  • nausea824
  • arthralgia780
  • drug hypersensitivity772
  • rash766
  • pyrexia736

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004102
2005103
2006130
2007103
2008126
2009174
2010307
2011290
2012376
2013272
2014192
2015311
2016327
2017353
2018355
2019563
2020554
2021376
2022519
2023527
2024717
2025891
2026453

Recalls

3 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Jul 30, 2014 · Class III · Terminated

    Failed pH Specification: A pH result of 2.9 was obtained at the 9 month stability test interval at 25C/60%RH. The registered specification for pH is 3.0 - 7.0

Shortages

FDA's drug shortage list.

  • Current · updated Nov 6, 2026

    Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03). Other

  • Current · updated Nov 6, 2026

    Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02). Demand increase for the drug

  • Current · updated Nov 6, 2026

    Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23). Other

  • Current · updated Nov 6, 2026

    Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52). Other

  • Current · updated Nov 6, 2026

    Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02).

  • Current · updated Nov 6, 2026

    Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22). Demand increase for the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Depo-Medrol (Methylprednisolone Acetate)

2024 spending

$25K

Beneficiaries

720

914 claims

Per beneficiary

$35

$15.58 per unit

View as table
YearSpending
2020$47,940
2021$26,290
2022$8,424
2023$20,857
2024$25,135

Part B: Depo-Medrol* (MethylprednIsolone Acetate*) · HCPCS J1010

2024 spending

$10.3M

Beneficiaries

890,806

1,297,268 claims

Per beneficiary

$12

2024 ASP limit $0.13 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$10,310,247

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,718 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.